Modality
Peptide
MOA
KIF18Ai
Target
BCMA
Pathway
Hedgehog
PSP
Development Pipeline
Preclinical
Oct 2021
→ Jul 2025
PreclinicalCurrent
NCT03074764
359 pts·PSP
2021-10→2025-07·Completed
359 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-07-248mo agoInterim· PSP
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3
Preclinical
Complet…
Catalysts
Interim
2025-07-24 · 8mo ago
PSP
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03074764 | Preclinical | PSP | Completed | 359 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| Ribosacituzumab | Roche | Approved | Cl18.2 | |
| RHH-8482 | Roche | Phase 1 | BTK | |
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| TAK-1836 | Takeda | Preclinical | EGFR | |
| REG-2328 | Regeneron | Phase 1 | BCMA | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA |